Research and development expenses for the second quarter of 2013 were $6.5 million, as compared to $8.7 million for the comparable quarter in 2012. For the six months ended June 30, 2013, research and development expenses were $15.1 million, as compared to $16.5 million for the same period in 2012.

Research and development expenses primarily relate to the following Dyax research and development initiatives: 1) KALBITOR medical support and post-marketing requirements; 2) development of a single-injection formulation of KALBITOR; 3) development costs associated with DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein; and 4) pass-through license fees paid by Dyax licensees under the LFRP.

Selling, general and administrative expenses were $10.2 million for the second quarter of 2013, as compared to $10.4 million for the comparable quarter in 2012. For the six months ended June 30, 2013, selling, general and administrative costs were $21.3 million, as compared to $20.8 million for the same period in 2012.

For the quarter ended June 30, 2013, Dyax reported a net loss of $8.4 million or $0.08 per share attributable to common stockholders, as compared to a net loss of $7.9 million or $0.08 per share for the comparable quarter in 2012. For the six months ended June 30, 2013, Dyax reported a net loss of $19.6 million or $0.19 per share attributable to common stockholders, as compared to a net loss of $19.2 million or $0.19 per share for the comparable period in 2012.

As of June 30, 2013, Dyax had cash, cash equivalents, and investments totaling $46.9 million, exclusive of restricted cash.

Financial Guidance

Dyax’s has reiterated its financial guidance for 2013:
  • Top-line total revenue to be in the range of $53-58 million, including
    • KALBITOR net sales in the range of $40-44 million.

Webcast and Conference Call

Date:
            Wednesday, July 24, 2013

Time:
5:00 p.m. ET

Telephone Access:

Domestic callers, dial 877-674-2415; reference the Dyax conference call

International callers, dial 708-290-1364
No passcode required.

Online Access:

Go to the Investor Relations section of the Dyax website ( www.dyax.com) and follow instructions for accessing the live webcast. Participants may register in advance.

 

A replay of the conference call will be available through July 29, 2013 and may be accessed by dialing 855-859-2056. International callers should dial 404-537-3406. The replay passcode for all callers is 11057012. The webcast will be archived on the Dyax website for an indefinite period of time.

About DyaxDyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key value drivers are the KALBITOR ® (ecallantide) business, DX-2930 and the internal pipeline, and the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.

If you liked this article you might like

Shire to Acquire Biopharma Company Baxalta in $32B Deal

The Nominees for Best Biopharma CEO of 2015 Are...

3 Drugs Stocks Moving The Industry Upward

Dyax (DYAX) Moving On Heavy Volume In The Pre-Market Hours

OPEC Begins Meeting Today, Saudis May Cut Oil Production